The global newborn screening market valued at $ 1,055.24 million in 2021, and is projected to reach $ 2,038.47 million by 2031, registering a CAGR of 6.8% from 2022 to 2031
Newborn screening test is the series of test performed during the first few days of your baby's life, usually by a hospital health care practitioner. A few drops of blood from a heel prick are placed on a special card, called a Guthrie card. this card, along with your baby's details, is mailed to a specialized state laboratory, which will test the blood sample for a variety of health disorders, including CF (cystic fibrosis). Newborn screening in certain states requires two blood samples, one at birth and the other a few weeks later. Newborn screening is essential for detection and early diagnosis of certain genetic, endocrine, and metabolic disorders, and are also tested for hearing loss and critical congenital heart defects (CCHDs).
The major factors that drive the growth of the global newborn screening market include increasing government support for newborn screening and development in screening technology. In addition, high birth rate and increasing incidence of neonatal disease propel the market growth. However, lack of improvement in healthcare infrastructure. Conversely, screening of genetic disorders and emerging market such as Brazil, China and India provide significant opportunities to key players in this market due to increase in birth rates and rise in disposable income.
The global newborn screening market is segmented into test type, technology, product type and region. According to test type, the market is categorized into blood test, hearing screening test, heart screening test. By technology, it is segregated into tandem mass spectrometry (TMS), molecular assay, immunoassays & enzymatic assays, hearing screen technology, pulse oximetry screening technology and others(DNA based assay and electrophoresis). on the basis of end user, the market is bifurcated into hospitals and clinical laboratories. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Ab Sciex LLC (subsidiary of Danaher Corporation), Perkinelmer, Inc., Waters Corporation, Natus Medical Incorporated, Masimo Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Covidien Plc, Ge Healthcare (subsidiary of General Electric Company) and Trivitron Healthcare.
Newborn screening test is the series of test performed during the first few days of your baby's life, usually by a hospital health care practitioner. A few drops of blood from a heel prick are placed on a special card, called a Guthrie card. this card, along with your baby's details, is mailed to a specialized state laboratory, which will test the blood sample for a variety of health disorders, including CF (cystic fibrosis). Newborn screening in certain states requires two blood samples, one at birth and the other a few weeks later. Newborn screening is essential for detection and early diagnosis of certain genetic, endocrine, and metabolic disorders, and are also tested for hearing loss and critical congenital heart defects (CCHDs).
The major factors that drive the growth of the global newborn screening market include increasing government support for newborn screening and development in screening technology. In addition, high birth rate and increasing incidence of neonatal disease propel the market growth. However, lack of improvement in healthcare infrastructure. Conversely, screening of genetic disorders and emerging market such as Brazil, China and India provide significant opportunities to key players in this market due to increase in birth rates and rise in disposable income.
The global newborn screening market is segmented into test type, technology, product type and region. According to test type, the market is categorized into blood test, hearing screening test, heart screening test. By technology, it is segregated into tandem mass spectrometry (TMS), molecular assay, immunoassays & enzymatic assays, hearing screen technology, pulse oximetry screening technology and others(DNA based assay and electrophoresis). on the basis of end user, the market is bifurcated into hospitals and clinical laboratories. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Ab Sciex LLC (subsidiary of Danaher Corporation), Perkinelmer, Inc., Waters Corporation, Natus Medical Incorporated, Masimo Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Covidien Plc, Ge Healthcare (subsidiary of General Electric Company) and Trivitron Healthcare.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the newborn screening market analysis from 2021 to 2031 to identify the prevailing Newborn Screening Market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the newborn screening market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global newborn screening market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product Type
- Instrument
- Consumables
By Test Type
- Blood test
- Hearing screening test
- Heart screening
By Technology
- Tandem Mass Spectrometry (TMS)
- Molecular Assays
- Immunoassays and Enzymatic Assays
- Hearing Screen Technology
- Pulse Oximetry Screening Technology
- Others
By End User
- Hospitals
- Clinical laboratories
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- Spain
- Rest of Europe
- France
- U.K.
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Ab Sciex LLC
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Covidien Plc
- Ge Healthcare
- PERKINELMER, INC.
- MASIMO CORPORATION
- Natus Medical Incorporated
- Trivitron Healthcare
- Waters Corporation
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: NEWBORN SCREENING MARKET, BY PRODUCT TYPE
CHAPTER 5: NEWBORN SCREENING MARKET, BY TEST TYPE
CHAPTER 6: NEWBORN SCREENING MARKET, BY TECHNOLOGY
CHAPTER 7: NEWBORN SCREENING MARKET, BY END USER
CHAPTER 8: NEWBORN SCREENING MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Newborn Screening Market,' the newborn screening market was valued at $1.1 billion in 2021, and is estimated to reach $2.0 billion by 2031, growing at a CAGR of 6.8% from 2022 to 2031.Newborn screening refers to a series of special tests which includes blood, hearing, and heart screening, done to one- to two-day-old infants, usually before they leave the hospital. This is use to check for any serious health disorders that do not show signs at birth. The tests often scan for genetic and metabolic abnormalities, hearing problems, specific heart problems, and other conditions that can hinder their development. Newborn babies that have health conditions may not exhibit any symptoms at infancy. If left untreated, the baby may develop serious problems, Newborn screening helps with the early diagnosis of these conditions so babies can begin treatment as soon as possible-before the disease even turns serious or so early interventions can be made.
The major driving factors of Newborn Screening Industry include increasing government support for newborn screening and development in screening technology. Furthermore, to high birth rate and increasing incidence of neonatal disease expected to supplement the newborn screening market growth. However, lack of improvement in healthcare infrastructure and limited number of trained professionals are expected to impede the market growth. Conversely, screening of genetic disorders and emerging market such as Brazil, China and India provide significant opportunities to key players in this market due to increase in birth rates and rise in disposable income.
On the basis of product, the consumables segment dominated the market in 2021. This segment is expected to exhibit a prominent growth rate, owing to increasing newborn disease prevalence and increasing newborn screening rate.
On the basis of test type, the blood test segment is expected to dominate the Newborn Screening Market trends and is expected to register a highest CAGR of 7.3% during the forecast period. owing to increase in the usage of DBS (Dry blood spot test) for serological diagnosis of infectious or autoimmune disease and easy and effective diagnosis as compare to other testing methods.
Depending on technology, the tandem mass spectrometry (TMS) segment dominated the Newborn Screening Market size in 2021. This segment is expected to exhibit a prominent growth rate, owing to cost effectiveness, high applicability and technology upgrades.
On the basis of end user, the hospital segment dominated the market in 2021, and is expected to exhibit prominent growth rate of Newborn Screening Market share, owing to rise in disposable income with rise in need for hospitalization for patients, Development in healthcare for infrastructure of hospitals and high-tech equipment in the hospitals further drive the market growth.
Region wise, North America accounted for more than 6.6% of the global market share in 2020, and is expected to remain dominant throughout the forecast period. This was attributed to the availability of newborn screening programs, favorable reimbursement policies and strong market players presence. Asia-Pacific is projected to register the highest CAGR of 7.9% during the forecast period, owing to the high population density, higher birth rate and the soaring prevalence of congenital diseases.
KEY FINDINGS OF THE STUDY.
Based on product, the consumables held the largest market share in 2021 and is expected to remain dominant during the forecast period.
Based on test, the blood test segment held the largest share in the global market in 2021
On the basis of technology, the tandem mass spectrometry (TMS) held the largest market share in 2021 and is expected to remain dominant during the forecast period.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 7.9% during the forecast period.
Companies Mentioned
- Ab Sciex LLC
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Covidien Plc
- Ge Healthcare
- PERKINELMER, INC.
- MASIMO CORPORATION
- Natus Medical Incorporated
- Trivitron Healthcare
- Waters Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 220 |
| Published | May 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1055.24 million |
| Forecasted Market Value ( USD | $ 2038.47 million |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
